Buy Rating for Connect Biopharma: Promising Clinical Data and Market Potential for Rademikibart

Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Connect Biopharma Holdings and keeping the price target at $7.00.

Brandon Folkes has given his Buy rating due to a combination of factors including the promising clinical data presented by Connect Biopharma Holdings for its drug, rademikibart. The recent analyses from the Phase 2b asthma program demonstrate the drug’s rapid onset of action and sustained improvement in lung function, particularly in patients with elevated biomarkers of type 2 inflammation. These findings support the potential for positive outcomes in the upcoming Seabreeze trials, expected to read out in 2026.
Additionally, the reduction in exacerbations and the dual value proposition of rademikibart as both an acute and maintenance therapy highlight its potential market impact. With a strong cash position to fund operations through key data readouts and a large addressable market, the stock presents a compelling risk/reward opportunity. The valuation is supported by a probability-weighted clinical net present value model, factoring in a significant potential for success in the U.S. market.